There’s a shortage of U.S. EpiPens and other allergic reaction treatments

The U.S. has a shortage of EpiPens and other allergic reaction treatments called epinephrine auto-injectors.

The issue was raised by advocacy group Food Allergy Research and Education this week as a growing national problem, and the Food and Drug Administration later added Mylan’s MYL, +3.56% authorized generic EpiPen and Impax Laboratories’ pre-filled auto-injector to its drug shortage list on Wednesday.

Mylan’s products have “intermittent supply constraints due to manufacturing delays from the manufacturing partner,” a Pfizer unit, and supply levels may vary, the FDA said, while Impax Laboratories Inc.’s IPXL, +0.00% products are in short supply because of an issue related to manufacturing practices.

>>> Original Source <<<